MedTrace Logo

A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval

NCT02537288 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2016-01-06

No results posted yet for this study

Summary

The purpose of this study is to assess the electrocardiogram (ECG) effects of fedovapagon dose administration relative to placebo in healthy adult male and female subjects.

Conditions

  • Healthy

Interventions

DRUG

Fedovapagon

DRUG

Moxifloxacin

DRUG

Placebo (for fedovapagon)

Sponsors & Collaborators

  • Vantia Ltd

    lead INDUSTRY

Principal Investigators

  • Georg Golor, PD Dr med · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02537288 on ClinicalTrials.gov